Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

Cannabidiol for the treatment of cannabis withdrawal syndrome: a case report.

Crippa JA, Hallak JE, Machado-de-Sousa JP, Queiroz RH, Bergamaschi M, Chagas MH, Zuardi AW.

J Clin Pharm Ther. 2013 Apr;38(2):162-4. doi: 10.1111/jcpt.12018. Epub 2012 Oct 24.

PMID:
23095052
2.

Nabiximols as an agonist replacement therapy during cannabis withdrawal: a randomized clinical trial.

Allsop DJ, Copeland J, Lintzeris N, Dunlop AJ, Montebello M, Sadler C, Rivas GR, Holland RM, Muhleisen P, Norberg MM, Booth J, McGregor IS.

JAMA Psychiatry. 2014 Mar;71(3):281-91. doi: 10.1001/jamapsychiatry.2013.3947.

PMID:
24430917
3.

Cannabinoid replacement therapy (CRT): Nabiximols (Sativex) as a novel treatment for cannabis withdrawal.

Allsop DJ, Lintzeris N, Copeland J, Dunlop A, McGregor IS.

Clin Pharmacol Ther. 2015 Jun;97(6):571-4. doi: 10.1002/cpt.109. Epub 2015 Apr 17. Review.

PMID:
25777582
4.

Effects of fixed or self-titrated dosages of Sativex on cannabis withdrawal and cravings.

Trigo JM, Lagzdins D, Rehm J, Selby P, Gamaleddin I, Fischer B, Barnes AJ, Huestis MA, Le Foll B.

Drug Alcohol Depend. 2016 Apr 1;161:298-306. doi: 10.1016/j.drugalcdep.2016.02.020. Epub 2016 Feb 23.

5.

The time course and significance of cannabis withdrawal.

Budney AJ, Moore BA, Vandrey RG, Hughes JR.

J Abnorm Psychol. 2003 Aug;112(3):393-402.

PMID:
12943018
6.

Oral delta-9-tetrahydrocannabinol suppresses cannabis withdrawal symptoms.

Budney AJ, Vandrey RG, Hughes JR, Moore BA, Bahrenburg B.

Drug Alcohol Depend. 2007 Jan 5;86(1):22-9. Epub 2006 Jun 12.

PMID:
16769180
7.

Nabilone therapy for cannabis withdrawal presenting as protracted nausea and vomiting.

Lam PW, Frost DW.

BMJ Case Rep. 2014 Sep 22;2014. pii: bcr2014205287. doi: 10.1136/bcr-2014-205287.

8.

[Cannabis withdrawal syndrome in patients with cannabis dependence only, and in patients with cannabis and opioid dependence].

Vorspan F, Guillem E, Bloch V, Bellais L, Sicot R, Noble F, Lepine JP, Gorelick DA.

Encephale. 2011 Sep;37(4):266-72. doi: 10.1016/j.encep.2010.12.007. Epub 2011 Feb 5. French.

PMID:
21981886
9.

Diminished gray matter in the hippocampus of cannabis users: possible protective effects of cannabidiol.

Demirakca T, Sartorius A, Ende G, Meyer N, Welzel H, Skopp G, Mann K, Hermann D.

Drug Alcohol Depend. 2011 Apr 1;114(2-3):242-5. doi: 10.1016/j.drugalcdep.2010.09.020. Epub 2010 Nov 2.

PMID:
21050680
10.

Interactions between cannabidiol and delta9-THC during abstinence in morphine-dependent rats.

Hine B, Torrelio M, Gershon S.

Life Sci. 1975 Sep 15;17(6):851-7. No abstract available.

PMID:
1238886
11.

Nabiximols combined with motivational enhancement/cognitive behavioral therapy for the treatment of cannabis dependence: A pilot randomized clinical trial.

Trigo JM, Soliman A, Quilty LC, Fischer B, Rehm J, Selby P, Barnes AJ, Huestis MA, George TP, Streiner DL, Staios G, Le Foll B.

PLoS One. 2018 Jan 31;13(1):e0190768. doi: 10.1371/journal.pone.0190768. eCollection 2018.

12.

The cannabis withdrawal syndrome.

Budney AJ, Hughes JR.

Curr Opin Psychiatry. 2006 May;19(3):233-8. Review.

PMID:
16612207
13.

Differential effect of cannabinol and cannabidiol on THC-induced responses during abstinence in morphine-dependent rats.

Hine B, Torrelio M, Gershon S.

Res Commun Chem Pathol Pharmacol. 1975 Sep;12(1):185-8.

PMID:
1237925
14.

Time-course of the DSM-5 cannabis withdrawal symptoms in poly-substance abusers.

Hesse M, Thylstrup B.

BMC Psychiatry. 2013 Oct 12;13:258. doi: 10.1186/1471-244X-13-258.

15.

[Cannabis: Use and dependence].

Dervaux A, Laqueille X.

Presse Med. 2012 Dec;41(12 Pt 1):1233-40. doi: 10.1016/j.lpm.2012.07.016. Epub 2012 Oct 5. French.

PMID:
23040955
16.

The quasi-morphine withdrawal syndrome: effect of cannabinol, cannabidiol and tetrahydrocannabinol.

Chesher GB, Jackson DM.

Pharmacol Biochem Behav. 1985 Jul;23(1):13-5.

PMID:
2994117
17.

Sex differences in cannabis withdrawal symptoms among treatment-seeking cannabis users.

Herrmann ES, Weerts EM, Vandrey R.

Exp Clin Psychopharmacol. 2015 Dec;23(6):415-21. doi: 10.1037/pha0000053. Epub 2015 Oct 12.

18.

Safety and side effects of cannabidiol, a Cannabis sativa constituent.

Bergamaschi MM, Queiroz RH, Zuardi AW, Crippa JA.

Curr Drug Saf. 2011 Sep 1;6(4):237-49. Review.

PMID:
22129319
19.

Case study: withdrawal syndrome in adolescent chronic cannabis users.

Duffy A, Milin R.

J Am Acad Child Adolesc Psychiatry. 1996 Dec;35(12):1618-21.

PMID:
8973068
20.

Lithium carbonate in the management of cannabis withdrawal in humans: an open-label study.

Winstock AR, Lea T, Copeland J.

J Psychopharmacol. 2009 Jan;23(1):84-93. doi: 10.1177/0269881108089584. Epub 2008 May 30.

PMID:
18515451

Supplemental Content

Support Center